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Small-cell lung cancer (SCLC) accounts for approximately 13% of all newly diagnosed 
lung cancer (LC) cases. This disease is correlated with heavy smoking. It is characterized 
by a rapid doubling time combined with a propensity to metastasize quickly and by 
neuroendocrine differentiation. In patients with locally advanced disease, the standard of 
care is concurrent radiation and platinum-doublet chemotherapy (PDCT). Patients with 
stage IV disease have also until recently been treated with PDCT. Even though a majority 
of SCLC cases initially responds to PDCT, almost all patients inevitably relapse. This 
thesis aims to deepen the knowledge of SCLC. 
Paper I was a population-based study, where we aimed to investigate the possible 
association between educational levels and overall death of Swedish SCLC patients. The 
patient population consisted of 4256 subjects. The key findings showed that educational 
level is an independent prognostic factor in Swedish men diagnosed with SCLC and among 
patients with Limited disease. 
In paper II, we performed a validation of the 8th TNM staging system on 706 SCLC cases 
and compared the system´s prognostic performance to the 6th and 7th TNM editions as well 
as to the older two-stage system that segmented patients as either having Limited Disease 
(LD) or Extensive Disease (ED). The study provided additional information supporting the 
robustness of the 8th TNM edition in prognostically categorizing SCLC and confirms its 
usefulness in clinical practice.  
In paper III, we conducted a real-world study on 545 consecutive cases during an eight-
year period. The aim was to understand in depth the treatment patterns of SCLC patients 
from Karolinska University Hospital. Another goal was to examine the outcome of SCLC 
patients upon re-challenge with PDCT. The survival outcomes for LD and ED SCLC 
patients were poor, correlating with previous studies. The results also showed that SCLC 
patients with sensitive relapse after first line PDCT may benefit from re-challenge.  
In paper IV, the expression of multiple biomarkers, including Notch1, Hes1, Ascl1, and 
DLL3, were analysed in a selected cohort of 46 SCLC patients. The study, in part, focused 
on how the expression patterns differed based on patients’ resistance or sensitivity to 
PDCT. We evaluated the prevalence of expression of these four biomarkers in human 
samples using biopsies and studied the potential association with survival and benefit from 
1st line PDCT. The study showed that Notch1 seems to be an independent prognostic factor 
in SCLC. Furthermore, a negative association between Notch1 and Ascl1 expression was 
observed.  
In summary, this thesis expands on the understanding of SCLC by analysing 
epidemiological trends, the impact of socioeconomic status, changes to classifying patients, 
and possible prognostic biomarkers.   
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1 Background  
1.1 Introduction 
Lung cancer (LC) is the deadliest form of cancer worldwide in both sexes. (1) The World 
Health Organization (WHO) divides LC into two main categories: non-small cell lung cancer 
(NSCLC) and small-cell lung cancer (SCLC). (2, 3) The majority of LC patients are 
diagnosed with NSCLC, with adenocarcinoma being the largest subtype (44%) followed by 
squamous cell carcinoma (26%) and large cell carcinoma (15%). (4) The proportion of LC 
that is classified as SCLC has decreased over the past decades from 20%-25% in the 1980s to 
around 13% today. (5, 6) SCLC is a rare disease in non-smokers, representing only 3% of 
cases. (7) The proportion of women diagnosed with SCLC has increased to 50% over the past 
few decades due to changes in tobacco consumption habits. (8) The risk of developing SCLC 
increases with age, with approximately 45% of cases are above 70 years. (5) 
1.2 Origins of SCLC 
SCLC cells originate from a sensory cell called neuroendocrine cell. (9) In 1926, Dr. WG 
Barnard identified certain mediastinal cells in the lungs. (10) At the time, such cells were 
thought to be “oat cell sarcomas”. However, in 1959, researchers correctly recognized that 
these neuroendocrine cells were in fact a separate and distinct form of LC, which today is 
known as SCLC. (11) 
SCLC is diagnosed by immunohistochemical staining, a diagnostic tool used to distinguish 
SCLC from other malignancies. The disease is characterized by small homogenous malignant 
cells, which are larger in size compared to lymphocytes. (12) The diagnosis SCLC can 
usually be determined by testing for thyroid-transcriptor factor-1 (TTF-1), and established 
neuroendocrine markers such as, synaptophysin, chromogranin, and CD56. (12-15) 
 
Figure 1 Morphology of SCLC  
Hematoxylin and eosin stained SCLC section (left) and positively stained CD56 in brown color of a SCLC 
section (right). Magnification 40x. Reprinted with permission from Elsevier  
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1.3 LC registries  
The Swedish Cancer Register (SCR) is maintained by the Swedish National Board of Health 
and Welfare. The SCR’s purpose is to monitor cancer incidence and survival in the Swedish 
population for medical research. (16) Since 1958, the SCR has been prospectively collecting 
data on new cancer cases, including linked information on medical data (anatomical site, 
method and date of diagnosis, and morphology), patient data (age, sex, and place of 
residence), and follow-up time (cause and date of death). (16) A notification of clinical, 
morphological, and autopsy-based cancer diagnoses is mandated by Swedish law, which 
ensures a high national coverage of around 95% when validated against the National Patient 
Register (NPR). (16) The SCR is considered extensive, with similar registries from other 
countries having significantly lower coverage percentages. For example, the Surveillance, 
Epidemiology, and End Results (SEER) program accounts for around 28% of the United 
States population. (17) 
The Swedish National Lung Cancer Register (NLCR) was founded in 2002 and aims to 
include all cases classified as LC according to the International Classification of Diseases for 
Oncology (code C34). (18) The NLCR collects a variety of patient data, including age, sex, 
smoking status, performance status (PS), diagnostic procedures, histopathology, and stage of 
disease at diagnosis. (19) The registry also includes information regarding planned treatment, 
lead times of referrals, and primary treatment decisions. The NLCR covers around 96% of 
Swedish lung cancer cases. (16, 19) 
The Longitudinal Integration Database for Health Insurance and Labor Market studies 
(LISA) was established in 1990 and contains annual registers on highest achieved education 
for all residents aged 16 and older in Sweden. In addition to information on educational level, 
the LISA also has data on country of birth, date of emigration, employment, cohabitation 
status and number of persons per household. (20, 21) 
Since 1961, the Swedish Cause of Death Register (CDR) has collected information on the 
date and underlying causes of death of every person in Sweden. According to recent statistics, 
the percentage of missing death certificates is less than 1%. (21, 22) 
The Lung Cancer Data Base Sweden (LCBaSe) was started for research purposes and is 
based on all LC patients registered in the NLCR from 2002-2016. The LCBaSe is composed 
of linkages between the NLCR and the SCR, CDR, LISA, NPR, Prescribed Drug Registry 
and Total Population Registry. (20) 
1.4 Epidemiology and socioeconomic factors 
Socioeconomic factors, including income, educational level, and accessibility to healthcare 
providers, contribute to health disparities. The literature has historically used income as the 
main measure of socioeconomic index (SEI). (23) However, using educational level as the 
SEI instead can avoid the risk of reverse causation bias. Thus, while a cancer diagnosis may 
result in reduced income, it should not affect educational level, which the subject in almost all 
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cases has already achieved. (23, 24) In addition, education may to a certain extent facilitate a 
lifelong choice of health attitude and behavior. (23) 
Other studies have investigated the potential association between SEI and cancer-specific 
mortality. (23, 25) In Sweden, everyone should have equal access to healthcare through a tax-
funded National healthcare system. However, studies on Swedish prostate cancer, breast 
cancer, and NSCLC patients have shown differences in survival outcomes among the various 
SEI subgroups. (20, 24, 26) Furthermore, a recent report on Swedish NSCLC patients showed 
a difference in diagnostic intensity and mortality among different SEI groups. (27) 
Less educated patients have been shown to be diagnosed with a more advanced stage of their 
cancer diagnosis. (28) This could possibly be explained by poorer compliance to certain 
screening programs (breast-, cervical-, colorectal-, and prostate- cancer). (29, 30) Another 
study has shown that patients with high education have a greater probability of receiving 
curative treatment compared to low educated cancer patients. (31) These factors may be less 
relevant to SCLC cases, since the majority of SCLC patients are diagnosed with metastatic 
disease. (32, 33) 
The aim of paper I was to investigate the potential influence of educational level (as the 
measure of SEI) on treatment patterns, lead times, and outcomes in Swedish SCLC patients. 
1.5 Clinical symptoms and prognosis 
The most frequent symptoms of SCLC include a cough, dyspnea, weight loss, and fatigue. 
Most patients are diagnosed within three months of symptom onset, reflecting a short tumor 
doubling time. (34) For stage I-III disease, the median survival ranges from 15 to 20 months 
and the five-year survival rate is approximately 10%. (35) In contrast, for patients with stage 
IV disease, the median survival is 8 to 13 months and the five-year overall survival (OS) is 
only 1%. (36) In Figure 2, the five-year OS for SCLC and NSCLC patients diagnosed in 
Sweden between 2012 and 2018 are presented. (19) 
 
Figure 2 Prognosis for Lung Cancer patients according to stage of the disease 
The overall survival for patients diagnosed with SCLC (n=3362) (left) and NSCLC (n=22132) (right) by stage of 
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1.6 Classification of SCLC according to the VALSG classification and TNM 
The classification systems used for SCLC patients are constructed according to the 
assessment of tumor burden at diagnosis and are key to determining prognosis. (37, 38) Early 
attempts to classify patients into subgroups have been performed to separate potentially 
curative patients from palliative ones. (5) In the late 1950s, Veterans’ Administration Lung 
Study Group (VALSG) developed the first staging system for SCLC, which divided cases 
into Limited Disease (LD) or Extensive Disease (ED). (38) LD encompasses tumors confined 
to one hemithorax with or without regional lymph node involvement and where the tumor 
burden can be effectively included in the same radiation portal. ED comprises everything 
beyond LD. (38, 39) The VALSG classification system was later elaborated by the 
International Association for the Study of Lung Cancer (IASLC) to encompass the 
contralateral mediastinal, hilar, and supraclavicular nodes into the definition of LD. (37) 
The tumor, node, and metastasis (TNM) classification system was developed in the 1980s to 
better stratify LC patients. (40) Since then, it has been periodically revised with updated 
editions. A major revision resulted in the 7th TNM edition in 2007, which included 81,495 LC 
patients out of which 12,000 were SCLC cases. (37, 41) The 7th TNM edition added new 
subcategories to the tumor size (T)- and metastasis pattern (M)-descriptors. (42) No new 
stage categories were introduced. (37) In the 7th TNM edition, pleural or pericardial 
dissemination (effusions or nodules) were no longer classified as having localized disease 
(T4). (42) This subgroup was instead included into the metastatic descriptor (M1a) in order to 
distinguish patients treated with chemotherapy (CT) alone. (43) Despite certain 
improvements, the 7th TNM edition had several weaknesses, including the fact that the 
population used in this edition was largely limited to patients of European or North American 
descent and radiological tools, such as 18F-FDG-PET/CT scan, were not yet implemented for 
clinical staging. (44) 
To further improve the TNM classification system, IASLC developed the 8th TNM edition, 
analyzing data of approximately 70,000 LC cases (among them 6,000 SCLC) diagnosed 
between 1999 and 2010 in 16 countries. (45) In the 8th TNM edition several new subgroups 
were added according to the size of the primary tumor (T-descriptor). (46) Two new 
subcategories were also added to the M-descriptor, with patients designated with a single 
metastasis into M1b, while subjects with more than one extra-thoracic metastasis were 
classified as M1c. (47) There were no changes to the lymph node (N-descriptor) between the 
TNM editions because of adequate prediction of prognosis. (48)  
The changes introduced between the 7th and 8th TNM editions are presented in Table 1, and 
the new stages introduced in the 8th TNM edition are outlined in Table 2. (45, 49)  
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Table 1 The changes between the 7th and 8th TNM editions.  
Descriptor 7th TNM 8th TNM 
T-descriptor   
</=1cm T1a T1a 
>1-2 cm T1a T1b 
>2-3 cm T1b T1c 
>3-4 cm T2a T2a 
>4-5 cm T2a T2b 
>5-7cm T2b T3 
>7 cm T3 T4 
Bronchus <2 cm from carina T3 T2 
Total atelectasis T3 T2 
Invasion of diaphragm T3 T4 
Invasion of mediastinal pleura T3 - 
M-descriptor   
Metastasis within the thoracic cavity M1a M1a 
Single extrathoracic metastasis M1b M1b 
Multiple extrathoracic metastasis M1b M1c 
Table 2 New stages introduced in the 8th TNM edition.  
Besides the VALSG classification, which was specifically developed for SCLC, the 8th TNM 
classification system was validated on predominantly NSCLC patients. (45) The VALSG 
classification remains in use for guiding the treatment of SCLC patients. Despite this, for 
diagnosing SCLC patients, the TNM system is generally encouraged. (45) Therefore, the goal 
of paper II was to validate the 8th TNM edition, specifically as it relates to SCLC patients.  
Stage T-descriptor N-descriptor M-descriptor 
IA1 T1a N0 M0 
IA2 T1b N0 M0 
IA3 T1c N0 M0 
IB T2a N0 M0 
IIIC T3/T4 N3 M0 
IVA Any T Any N M1a/M1b 
IVB Any T Any N M1c 
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1.7 Radiological tools used in SCLC diagnosis 
The diagnosis of SCLC is highly dependent on the different radiological modalities. (50) All 
radiological tools described below are important for accurately staging SCLC patients and are 
used either separately or in combination to determine the appropriate treatment option for 
each patient. 
1.7.1 The role of CT scan  
The first step of identifying and staging SCLC patients is to perform a computed tomography 
scan (CT scan) of the thorax and upper abdomen. This radiological modality is performed to 
evaluate the tumor burden and the effect of oncological treatments. (50)   
 
Figure 3a CT scan thorax/abdomen of a SCLC patient. A CT thorax/abdomen scan performed on a SCLC 
patient showing a centrally localized tumor prior to initiating palliative chemotherapy.  
1.7.2 The role of 18F-FDG-PET/CT scan  
Fluorodeoxyglucose (FDG)-positron emission tomography scan (18F-FDG-PET/CT scan) is a 
radiological method using the fluorodeoxyglucose radioisotope that is administered into the 
patients. It is then taken up by high-glucose- using cells, including tumor cells. (51) 
Therefore, this radiological modality combines functional (by 18F-FDG-PET) and anatomical 
information (by CT scan). (52) 18F-FDG-PET/CT scan is used in SCLC patients to more 
precisely assess mediastinal lymph node status and exclude distant metastasis prior to 
initializing therapy with curative intent. (52, 53) Previous reports have shown that adding 18F-
FDG-PET to CT scan improves accuracy of staging and can result in a change of treatment. 
(44, 54, 55) The usage of 18F-FDG-PET/CT scan became part of clinical practice in Sweden 
in 2008. 
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Figure 3b 18F-FDG-PET/CT scan of a SCLC patient 18F-FDG-PET/CT scan performed on a SCLC patient 
with a lymph node conglomerate located in the mediastinum with a high FDG-uptake and a primary tumor in the 
upper right lobe. 
1.7.3 The role of CT scan and MRI of the brain 
At the time of diagnosis, 15%-20% of SCLC patients have brain metastases, and the risk of 
development increases during the course of the disease. (56) The absence or presence of brain 
metastasis guides the treatment of SCLC patients. (57, 58) Therefore, it is recommended that 
SCLC patients receive a CT scan and MRI of the brain prior to initializing therapy to identify 
potential intracranial metastases. (56, 59) An MRI is better at finding small brain lesions 
compared to a CT scan of the brain. (56) 
1.8 Tumor biology and signaling aberrations in SCLC 
SCLC is characterized by a rapid tumor growth and a high degree of genomic alterations. 
(60) It has been suggested that most of the mutations observed in SCLC are passengers; they 
do not contribute to growth. This makes identifying the relevant driver mutations more 
difficult. (60) Whole genome sequencing performed on human SCLC samples has not found 
evidence of mutually exclusive targetable driver oncogenes. (61) The tumor suppressor genes 
TP53 and RB1 are inactivated in 90% and 65% of SCLC cases, respectively. (62) Mutations 
in targetable oncogenes, such as epidermal growth factor receptor (EGFR), are rarely found 
in SCLC. (63) However, recent publications suggest that SCLC may be subcategorized into 
four distinct types; SCLC- Ascl1(A) - NeuroD1(N), - YAP1(Y), and - POU2F3(P), with each 
letter representing the main transcription factor involved in each subtype. (63) The 
neuroendocrine-derived subgroup, SCLC- A, is the most common (70%). (63) The SCLC-Y 
and SCLC-P subtypes lack neuroendocrine features and have a different origin and growth 
pattern when compared to the SCLC-A subtype. (64, 65) The SCLC-Y and SCLC-P subtypes 
include a small proportion of SCLC patients. (63) 
1.9 Notch signaling pathway activation (Notch1 and Hes1) 
The Notch signaling pathway regulates several cellular processes in healthy individuals, 
including cell differentiation during both embryonic and adult development. (66, 67) The 
Notch pathway is also relevant in solid tumors, being either pro-tumorigenic or tumor-
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suppressive, depending on the cellular context. (68) In certain cancers, including malignant 
melanoma and mesothelioma, the Notch signaling pathway acts as an oncogenic driver. (69, 
70) 
The Notch pathway is regulated by a short-range cell to cell signaling. (71) It consists of 
several receptors (Notch-1 to 4), and is inactivated in a majority of SCLC cases. (67, 72) The 
Notch1 receptor has been described as the main Notch receptor involved in regulating the 
proliferation of neuroendocrine cells. (66, 73) Notch1 has a higher affinity at the ligand- 
binding site compared to other Notch receptors. (74, 75) Some of the proteins regulated by 
Notch1 have been identified. One such protein is the hairy/enhancer of split 1 (Hes1), a 
transcription factor that controls neuroendocrine cell differentiation. (76) The consequence of 
Hes1 is among other things inhibition of transcription of the neuroendocrine transcription 
factor, achaete-scute complex homologue 1 (Ascl1). (67, 76) This subsequently leads to a 
switch towards proliferation of non-neuroendocrine cells, which are slow growing and have a 
seemingly chemo-resistant feature to platinum. (71, 77) 
Notch signaling activation occurs between different cells when a ligand binds to its receptor, 
in trans. (78) The Golgi apparatus is the cellular localization for generation of Notch receptor 
proteins in which both protein synthesis and peptidase processing takes place generating an 
intermediate form of the Notch receptor. When a ligand binds onto the Notch receptor at the 
cell surface, proteolytic cleavage (S3 cleavage) of the Notch receptor by γ-secretase is 
triggered, resulting in release of the Notch intracellular domain (NICD) into the nucleus, 
where it induces transcription of the target genes, including Hes1. (78) This results in 
activation of the Notch signaling pathway. The activation is transient as the endogenous 
NICD degrades rapidly and is present at Notch target promoters only in response to the 
ligand. (67, 72) A simplified illustration of this Notch signaling activation is illustrated in 
Figure 4a, below.  
1.10 Notch1 signaling pathway inactivation (Ascl1 and DLL3) 
The Notch signaling pathway is inactivated by Notch ligands, which includes the 
transmembrane proteins; Delta-like ligand-1, 3, and 4 (DLL1, DLL3, DLL4) and Jagged 1 
and 2 (JAG1 and 2). (72) DLL3 differs from the other Notch ligands by having a smaller 
amount of epidermal growth factor (EGF)-like repeats. (79) DLL3 expression is regulated by 
Ascl1, a transcription factor that induces neuroendocrine cell proliferation and regulates the 
proliferation of pro-oncogenes such as Sox2, Myc-L and BCL-2. (80-82) When expression of 
Ascl1 is silent, the DLL3 expression also seems to be suppressed. (83) Furthermore, studies 
have shown that ASCL1 and Notch1 expression have a mutually exclusive expression 
pattern. (84, 85) 
Notch signaling inactivation occurs when DLL3 binds to its Notch receptor within the same 
cell (cis-interaction), in an autonomous pattern. (86, 87) The DLL3 expression is found in the 
cytoplasm of normal tissues, while in SCLC cells the ligand is expressed homogeneously on 
the cell surface. (88) When DLL3 binds to Notch receptor on the cell membrane, in cis, 
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Notch1 is relocated to the Golgi apparatus and becomes inactivated. (67) The inactivation of 
Notch signaling pathway results in neuroendocrine cell proliferation, which is believed to be 
more sensitive to platinum CT. The Notch signaling pathway inactivation is show in Figure 
4b (71, 77) 
.  
Figure 4a Notch signaling activation.  
1. Mindbomb is a protein that ubiquitinates and activates the Notch ligand(s) on the signaling sending 
cell and then binds to the Notch receptor, in trans, on the plasma membrane of the receiving SCLC 
cell. 2. The S3 cleavage via the proteases, y-secretase, results in releasing the NICD from the 
transmembrane portion of the Notch receptor and moves the NICD to the nucleus where it activates 
Notch target genes such as Hes1. 3. The activation of Notch signaling pathway results in a non-
neuroendocrine cell proliferation, which is believed to be more resistant to platinum CT.  
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Figure 4b Notch signaling inactivation 
1. Ascl1 transcription factor activates the Notch ligand (DLL3). DLL3 moves to the cell membrane 
where it binds to the Notch receptor, in cis, and competes for the same binding site as the sending cell. 
2. When DLL3 has successfully, the release of NICD is inhibited and Hes1 is subsequently not 
expressed. 3. The inactivation of Notch signaling pathway results in a neuroendocrine cell 
proliferation, which is believed to be more sensitive to platinum CT. 
1.11 Treatment of SCLC 
There are many different treatment options administered to SCLC patients depending on the 
stage of the disease and the patient’s PS. (89)  
1.11.1 Surgery 
Surgery is not the main treatment for patients with SCLC as surgical resection of the primary 
tumor is only indicated for those subjects who present with a solitary pulmonary nodule 
without mediastinal involvement or distant metastasis. (33) In the IASLC database, only 4% 
of SCLC cases underwent surgery. (33) There are no randomized clinical trials (RCT) that 
have compared surgery vs. surgery followed by adjuvant CT or chemo-and radio-therapy 
(CRT). (90) However, in an observational study, patients receiving adjuvant CT (with or 
without radiation) had an improved five-year OS compared to those who performed surgery 
alone (53% vs. 40%, respectively). (91) Today, adjuvant CT is recommended for SCLC 
patients who have undergone tumor resection. (90, 92) Patients with a lymph nodal 
involvement may be considered to receive adjuvant CRT. (93) 
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1.11.2 Concomitant CRT for stage I-III disease 
The combination of CRT is the standard of care for patients whose tumors are considered 
unresectable but may be potentially cured (stage I-III disease). Two meta-analyses have 
demonstrated that CRT significantly improves survival outcomes compared to CT alone. (94, 
95) Administering RT in combination with CT (concomitant) results in better survival 
outcomes than using RT after CT (sequential). (94, 96) The most frequent start of RT is after 
the first cycle of CT. (97) The PDCT regimen is the preferred CT administered in the first-
line (1st line) setting of stage I-III disease. 
There remains uncertainty regarding the optimal radiation dose and fractionation. The most 
frequently used schedule today is a total RT dose of 45 Gray (Gy) delivered in 30 fractions, 
twice per day (bid). An RCT from 1999 showed that the twice per day (bid) schedule was 
superior compared to a once per day schedule (5-year OS of 26% vs. 16%). (98) The main 
difference between these schedules appears to be the temporary acute toxicity, with an 
increase in grade III esophagitis when using the bid schedule (27% vs. 11%, p < 0.001). (98) 
1.11.3 PCI for patients with stage I-III disease treated with CRT 
The general recommendation for patients who have responded to CRT is prophylactic cranial 
irradiation (PCI) in order to prevent the development of brain metastases. (99) Two meta-
analyses have evaluated the role of PCI in patients who achieved complete remission after 
CRT. (99, 100) The results from the first study showed that there was a significant decrease 
in incidence of brain metastases and mortality with PCI compared to observation with no 
treatment (hazard radio 0.46; 95% CI 0.38-0.57). (99) A second meta-analysis evaluating 
twelve RCTs reported similar findings. (100) Today, the most common PCI schedule used in 
Sweden is 2.5 Gy delivered in 10 fractions, once per day. (19) 
1.11.4 Systemic 1st line CT for stage IV disease 
Patients who are diagnosed with stage IV disease are generally recommended systemic 1st 
line treatment with PDCT. (35) The treatment in the 1st line setting had remained unchanged 
for several decades until the recent introduction of Atezolizumab (anti PD-L1 blockade 
inhibitor), which is administered together with PDCT. The results from a study, known as the 
Impower-133, found a two month prolonged median OS in favor of the experimental arm — 
Atezolizumab together with PDCT rather than PDCT alone (12.2 months vs. 10.2 months, 
respectively). (101) The combination of PDCT together with Atezolizumab as maintenance 
therapy became approved by the U.S. Food and Drug Administration (FDA) in 2019. (102) 
In multiple RCTs, PDCT appears to be a more effective CT combination than older regimens 
such as cyclophosphamide, epirubicin, and vincristine. (103, 104) Carboplatin and cisplatin 
are the two types of platinum-agents that can be used in the PDCT regimen. Carboplatin is 
typically preferred to cisplatin, because carboplatin has a favorable toxicity profile. (105) 
(106) However, a meta-analysis found no statistically significant differences in survival 
outcomes between the two platinum agents. (107) There are also two different kinds of CT 
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agents used together with platinum; irinotecan and etoposide. (108) Etoposide is more 
frequently used in the Western world, while irinotecan is preferred in Asian populations. Four 
RCTs have compared these two agents together with platinum in the 1st line setting. The 
results showed no significant survival differences, with less hematologic and more 
gastrointestinal toxicity with irinotecan. (108-111)  
1.11.5 Re-challenge with PDCT in 2nd line setting for stage IV patients  
Most SCLC patient inevitably progress after receiving PDCT. Previous studies have shown 
the difficulty in treating these patients beyond the 1st line setting, because of platinum 
resistance. (112, 113) Relapsed patients survive only 2 to 4 months without second-line (2nd 
line) therapy. (114, 115) Re-challenge is defined as the administration of the same PDCT 
regimen provided in the 1st line setting. (116) Patients who have a longer duration without 
relapse after receiving 1st line PDCT will benefit more from re-challenge than patients with a 
shorter time before relapse. (116) According to this principle, relapsed patients are defined as 
either “sensitive” or “refractory” to PDCT. (114) The definitions of these subgroups differ 
between studies. The most frequently used definitions for “sensitive” and “refractory” relapse 
are defined as progression-free survival (PFS) of longer or shorter than 90 days after 
completion of CT, respectively. (114, 117, 118) Patients with “sensitive” relapse are 
recommended re-challenge with PDCT, while patients with "refractory” relapse should 
receive another CT regimen. These recommendations are based on several studies. (116, 117, 
119, 120)  
Other CT agents used in the 2nd line setting include taxanes, vinorelbine, gemcitabine, and 
temozolomide. These are usually administered as monotherapy and have response rates 
around 10%-15%. (121-124) 
1.11.6 Consolidating RT for stage IV 
Patient with stage IV disease, who have a complete response of distant metastasis and 
residual disease limited to the thorax after 1st line therapy, can be treated with consolidating 
RT to the thorax. (125, 126) The rationale for this treatment approach is to improve local 
control of the remaining tumor burden and ultimately prolong the survival. (125, 126) In an 
RCT, patients receiving 30 Gy to the residual tumor in the thorax had a longer median OS 
compared to the observational group. (125) The survival curves diverged after 18 months, 
with a statistically significant longer two-year OS in favor of the RT group, 13% vs. 3%, 
respectively (p = 0.004). (125) Because of this trial, consolidating RT has been used for stage 
IV patients more frequently during the past years. (125) 
1.11.7 PCI for stage IV disease 
The rationale of administering PCI in stage IV patients who have responded to 1st line CT is 
to decrease the risk of developing brain metastasis and thereby improve survival. (127) 
However, the prognostic impact of PCI in stage IV remains uncertain, as RCTs have shown 
conflicting results. (127, 128) A phase III trial conducted in Europe (n=286) randomized 
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patients 1:1, receiving either PCI or observation. (128) A brain MRI was not a requirement 
prior to PCI for this study, which meant that some patients may have had brain metastasis 
prior to initializing the therapy. (128) The results showed that patients treated with PCI had a 
statistically significant decreased risk of developing symptomatic brain metastases after a 
one-year follow-up (15% in the PCI group vs. 40% in the observational group developed 
brain metastasis). A Japanese trial (n=224) had a similar design, but patients were required to 
have performed an MRI of the brain prior to initializing PCI, and the presence of brain 
metastasis was an exclusion criterion. (127) The results from this study did not show a 
survival benefit for patients receiving PCI. The general recommendation for stage IV patients 
is currently to limit the use of PCI to those patients that have a complete response to 1st line 
CT and have a PS of 0-1. (19) 
1.11.8 Systemic 3rd line therapy for stage IV disease 
A minor proportion of SCLC patients have a PS which allows them to receive a third-line (3rd 
line) treatment. For those who are eligible, the survival outcomes are generally poor. (119) 
The only FDA approved drug in the 3rd line setting is an immunotherapy, nivolumab (anti-
programmed cell death receptor 1) antibody, with a response rate of less than 20%. (129) 
Other treatment options depend on the individual patient’s treatment history and may include 
a single-agent CT if the patient has already progressed on PDCT. (130) 
1.11.9 Role of molecular targeted agents in SCLC 
Several molecular targeted agents have been tested in phase I and phase II clinical trials for 
1st, 2nd, and 3rd line SCLC patients, as well as maintenance after 1st line. (131-133) Some of 
these agents act broadly on the tyrosine kinase signaling pathways (for example, sunitinib, 
bevacizumab, and everolimus). The phase II and phase III clinical trials testing these drugs 
have all shown poor response rates as well as poor tolerability when used alone or in 
combination with PDCT. (134-137) Furthermore, therapies targeting other signaling 
pathways including epidermal growth factor receptor (EGFR), PI3K/AKT/mTOR, and 
insulin-growth factor receptor (IGFR), have also demonstrated poor efficacy. (138, 139) 
One of the most promising agents developed recently is the so called Rovalpituzumab 
Tesirine (Rova-T), an antibody-drug conjugate (ADC) composed of a humanized DLL3-
specific IgG1 monoclonal antibody, a protease-cleavable linker, and a DNA cross-linking 
agent pyrrolobenzodiazepine (PDB). (81) Rova-T has been shown to bind DLL3 with high 
affinity on the cell surface. Internalization to the lysosome occurs rapidly, resulting in the 
cleavage of the linker and release of the toxin, which subsequently leads to a cell-cycle arrest. 
(81, 86) In a patient derived xenograft (PDX) model, mice treated with Rova-T had a 
prolonged response compared to mice treated with platinum CT. PDX tumor models that 
were resistant to platinum also showed responses to Rova-T. (81) 
In a first-in-human, open-label phase I study, 11 (17%) patients receiving Rova-T achieved 
durable responses and 35 (54%) patients had stable disease (SD). (140) Thirty-nine patients 
provided tumor samples for analysis of DLL3 expression. Twenty-nine assessable patients 
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had DLL3-high tumors (> 50% or more tumor cells by IHC). None of the 10 patients with 
DLL3-low tumors (< 50%) showed a clinical response. Rova-T was found to have 
unacceptable delayed toxicity in humans, such as pleural effusion. (140) One reason may be 
that the PBD toxin stays in the systemic circulation because of a premature lysis of the linker 
attached to the PBD toxin. This subsequently leads to severe toxicity since the DLL3 ligand 
is not expressed on the cell surface of normal tissues. (141) 
Rova-T has been investigated in several RCTs without showing any survival benefit. (142) 
These results have been disappointing considering the promising antitumoral effects of Rova-
T in mouse models. Further studies are needed to modify the molecule, for example by 
adding an alternative cytotoxic payload, to achieve acceptable tolerability.  
The timeline for the development of therapies in SCLC is described in Figure 5.  
 
Figure 5 Timeline of treatment options in SCLC from the 1980s to 2020. 
The development of treatment options for SCLC with regards to chemotherapy, radiotherapy, 
immunotherapy and different combinations. Abbreviations; LS- Limited stage, ES- Extensive stage, PCI- 
Prophylactic brain irradiation, B.i.d- twice per day. 
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2 Aims of the Thesis 
The purpose of the thesis was to expand on the understanding of SCLC; epidemiological 
trends and treatment patterns, changes to classifying patients and prognostic biomarkers. The 
specific aims for each paper were;  
Paper I was performed to investigate if there was an association between educational status 
and overall death of Swedish SCLC patients. It also examined if educational level influenced 
management and lead times.  
Paper II aimed to discover if the 8th TNM staging system could provide additional 
prognostic information compared to the previous 6th and, 7th TNM versions and the older 
VALSG classification system.  
Paper III evaluated the treatment patterns of SCLC patients. Another goal was to 
investigate the outcome of SCLC patients upon re-challenge with PDCT, and associations 
between clinical characteristics and survival outcomes.  
Paper IV aimed to analyze the prevalence of the expression of Notch1, Hes1, Ascl1, and 
DLL3, and the potential association of these four biomarkers to sensitivity to PDCT, 
prognosis, and clinical characteristics of SCLC.
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3 Patients, Material, and Methods 
3.1 Patient Cohort 
All four studies were based on retrospectively collected data from registries and patient files. 
The data for paper I was obtained from the LcBase, the NLCR, and several other population-
based registers in Sweden, and covered SCLC patients diagnosed between 2002 and 2011. 
For paper II, III, and IV, the patient data was obtained from the NLCR with some clinical 
characteristics also collected from each individual health record file. For paper II and III, 
SCLC cases were obtained over an eight year time period, from 2008 to 2016. In paper IV, all 
patients’ samples were retrieved from the Karolinska University Hospital, diagnosed with 
SCLC between 2008 and 2015. The cohort was highly selected depending on the amount of 
biopsy material, PDCT administered in 1st line setting, and follow-up data in order to evaluate 
the specific aims of the study. These strict criteria for paper IV resulted in excluding certain 
cases. All projects were undertaken with approved ethical and regulatory permissions (EPN 
2012/1162-31/4, 2016-8/31), as well as permission from the Stockholm medical biobank 
(BBK 1693 FUB 2016087). 
3.2 Re-classifying patients according to the TNM classification 
In paper II, each case was re-classified from the VALSG classification to the different TNM 
editions (6th, 7th, and 8th) by using all available radiological scans at the time of diagnosis. The 
radiological scans available were reviewed; including CT scan of the thorax and abdomen, 
18F-FDG-PET/CT scan, CT/MRI scan of the brain, and ultrasound of the liver. Radiological 
scans that were difficult to assess were reviewed together with an experienced radiologist.  
3.3 RWD analysis and definitions of treatment patterns and outcomes 
Real-world data (RWD) analysis means data collected for the purpose of evaluating the 
treatment outcomes for patients not treated in clinical trials. RWD analyses can be used to 
support regulatory decision-making and to guide clinical practice. (143) 
In SCLC patients, the survival outcomes have been shown to be worse in a real-world setting 
compared to RCTs (including the observational group). Thus, a matched comparison analysis 
showed a survival benefit for patients treated in an RCT compared to a real-world setting. 
(144, 145) One of the suggested explanations may be that patients enrolled in RCTs are a 
small and highly selected subgroup, which includes younger subjects who have a better PS 
compared to patients in clinical practice. (146-148) This highlights the limitations of 
extrapolating data from RCTs to a real-world setting.  
The definitions of survival outcomes (PFS and OS) were important for evaluating the results 
presented in paper III and IV. In paper III, the PFS was defined as the start of each line of CT 
until documented progression either clinically, on a radiological scan, or death. The definition 
for OS was the same for both papers, defined as the interval between the date of initiating 
each line of CT until death. (149) 
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However, the definition for platinum sensitivity to 1st line PDCT differed between the papers. 
In paper III, the “sensitive” subgroup only included patients that relapsed after PDCT and had 
a PFS of longer than 180 days after start of 1st line, since the aim was to evaluate the cases 
that were eligible for re-challenge. In paper IV the “sensitive” subgroup included all patients 
with a PFS of longer than 90 days after completion of PDCT, regardless if relapse occurred, 
since the aim was to investigate the sensitivity of platinum CT with regards to biomarkers.  
3.4 Immunohistochemistry 
Immunohistochemistry (IHC) is an established routine diagnostic method that uses antibodies 
to detect the localization and staining patterns of proteins in a tumor specimen. (150, 151) 
This diagnostic method is widely available and cost-efficient with a rapid turnaround time, 
making it the foundation of diagnosing SCLC. (151) In paper IV, the protein expression was 
determined using IHC on 4-μm-thick formalin-fixed, paraffin-embedded (FFPE) sections. 
(152) The Notch1, Hes1, and Ascl1 antibodies were applied manually, and several 
concentrations for each antibody were tested on human SCLC control cases in order to 
determine the optimal concentration. Two DLL3 antibodies were also tested using western 
blot and IHC, with poor results. (153) Therefore, when the automated immunostaining 
instrument (Ventana platform) for the DLL3 antibody became commercially available, it was 
used for paper IV. (154, 155) 
The FFPE sections were de-paraffinized in xylene and rehydrated in alcohol. To visualize the 
primary antibody binding a secondary antibody was applied. For each case, one hematoxylin-
eosin staining was performed and a positive/negative control for each biomarker was 
performed according to the manufacturer’s instruction. (156) 
The IHC evaluations was performed by one pathologist (L.K), who was blinded to the 
clinical data. The number of positive tumor cells was counted under high magnification (x20 
and x40). The tumor cells were counted in a quantitative manner and three random and non-
overlapping fields (with approximately 100 tumor cells per field, a total of 300 tumor cells 
per specimen). (157) The scoring of IHC staining were made into four categories according 
to the number of positive tumor cells stained; 0: No positive cells, 1; ≥1-25% positive cells, 2; 
≥26-50 % positive cells, 3; ≥51-75% cells, 4; ≥76% positive cells. The staining intensity was 
defined as any positivity in the tumor cells of each specimen as previously described. (158, 
159) 
Of the analyzed markers only DLL3 had a previously established cut-off between low vs. 
high expression (more or less than 50% of neoplastic cells, respectively). (140) For the other 
markers; Notch1, Hes1, and Ascl1, a cut-off was established based on sensitivity to PDCT 
using a dichotomizing score with receiver operating characteristic (ROC) curve analysis. The 
hypothesis was that Notch1 and Hes1 high expression would be more “refractory” to PDCT, 
while Ascl1 high expression be more “sensitive” to PDCT. The most statistically significant 
cutoff for each biomarker was defined as the point on the ROC curve giving the smallest 
distance to the point; 1-specificity, sensitivity = (0,1). (160) 
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3.5 Statistical analysis 
Two statisticians analyzed the data collected for paper I-IV in the thesis. Established 
prognostic clinical factors for each paper were included in uni- and multi- variate cox 
regression analysis using hazard ratio (HR) of 95% confidence interval (CI). Statistical 
significance was defined as p< 0.05. (161) For paper II, III, and IV, the survival models were 
compiled with the Kaplan-Meier curves and the log-rank test. (162) The correlation between 
the different biomarkers in paper IV was analyzed using Pearson’s correlation coefficient. 
(163) 
Statistical analysis presented in paper II was performed using the JMP software version 5.1.2, 
while R 3.5 (R Foundation for Statistical Computing, Vienna, Austria) was used in paper I 
and III. The statistical analyses for paper IV was carried out using SPSS© version 25 (IBM 
Corp, Armonk, NY, USA). 
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4 Results and Discussion 
4.1 The influence of educational level on outcome of SCLC patients (Paper I) 
Paper I aimed to explore a potential association in SCLC patients between educational level 
and death. This included examining if educational level influenced management, lead times, 
and prognosis of SCLC patients over a 10-year period. These research topics had not 
previously been explored in a SCLC cohort.  
We identified a large number of patients for this nationwide register-based study (n=4256). 
The median age at diagnosis was 69 years (Interquartile range of 64-75), 50.3% were women, 
and the majority of patients were diagnosed with ED (74.4%). Over 50% of cases had low 
education, while 39% had a medium level of education and 11% of the patients were 
categorized as having high education.  
The study had a number of key findings. With respect to lead time and treatment patterns, 
there were no significant differences between patients with low, medium, and high 
educational levels.  
However, educational level was found to influence prognosis in certain populations groups. 
Men with a high educational level had a better prognosis (high versus low: HR 0.84, 95% CI 
0.73-0.98). This association was not observed in women. (HR 0.92, 95% CI 0.78-1.09). The 
reason men with a lower education had a worse prognosis may be explained by the rate of 
smoking cessation after diagnosis. Men with a low education were more likely to continue 
smoking post-diagnosis compared to those with high education in a previous study. (164) It is 
known that continued smoking after being diagnosed with LC reduces the efficacy of 
oncological treatments and therefore could result in a worse prognosis. (165, 166) This 
explanation is a hypothesis, since data on smoking cessation could not be obtained from the 
registries.  
High educational level was also a statistically significant prognostic factor in LD patients 
(HR 0.76, 95 % CI; 0.58-0.98). This was not found in ED patients. Since SCLC often relapse 
after curative intended treatment, the adherence to follow-up visits and radiological scans are 
crucial. It could be speculated that lower educated patients may lack knowledge on the 
importance of follow-up visits, especially if clinical symptoms related to relapse appears.  
The underlying causes contributing to differences between educational level remain unclear, 
but have been discussed in relation to management of the disease and the role of the 
healthcare system. (23) This study found that socioeconomic differences exist in SCLC 
patients, which is in accordance with reports on patients with other cancer diagnoses. (20) 
In addition to exploring educational level the study investigated other SEI factors, such as 
cohabitations status. A poorer prognosis was observed in women living alone (HR 1.15, 95% 
CI; 1.05-1.26), which was not seen in men. This is in contrast to results from other studies 
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where it was shown that cohabitation status was a more important prognostic factor in men. 
(167)  
The strengths of this study were that almost all SCLC patients from 2002 to 2011 were 
included in the study and large amounts of patient data for these patients could be analyzed. 
A limitation was that data on smoking cessation could not be obtained from the registries. 
Another limitation was that the study only included patients diagnosed until 2011, which 
limits the extrapolation of data to today’s setting, since there is a trend towards patients 
receiving more consolidating RT and less PCI during the past decade. (36) 
4.2 Validation of the 8th TNM classification for SCLC in a retrospective study from 
Sweden (Paper II) 
The applicability of the TNM classification system has previously been studied mainly on 
small cohorts with stage I and II disease. (168-170) The results from these studies do not 
extrapolate to a majority of SCLC cases, since they are predominantly diagnosed with stage 
IV disease. (171) Paper II included a large patient cohort (n= 706), with most patients having 
locally advanced or metastatic disease. The aim of this study was to investigate if the 8th 
TNM edition can be used to classify SCLC patients and compare its prognostic performance 
to the older TNM editions and the VALSG definitions.  
The results from this study showed that tumor size (T) and nodal involvement (N) were 
important prognostic subgroups in the 8th TNM edition, with poorer prognosis observed in 
patients with larger tumors or more extensive nodular involvement. The proportion of SCLC 
patients with a single metastasis (M1b) was low, as expected, since SCLC usually presents 
with a larger metastatic burden. Patients with a M1b disease had a better prognosis compared 
to subjects with pleural dissemination or multiple extrathoracic metastasis, M1a and M1c, 
respectively. In recent years, the concept of oligometastatic disease has been incorporated 
into clinical trials for NSCLC patients were survival outcomes have improved in patients 
treated aggressively with local therapies such as stereotactic body radiation therapy (SBRT) 
compared to observation. (172) Patients with M1a disease had similar prognosis with M1c, 
illustrating the difficulty of treating SCLC patients with pleural dissemination.  
The proportion of stage I and II patients was low in this study, which makes the results from 
these subgroups difficult to interpret. In previous reports, stage I and II patients, had a better 
prognosis compared to advanced stage disease. (173) A large proportion of patients migrated 
to three new stage subgroups in the 8th TNM edition; IIIC, IVA, and IVB, which illustrates 
the importance of these subgroups. Patients with stage IIIC disease had a poor prognosis, 
similar to stage IVA disease. This illustrates the difficulty of effectively treating subjects with 
CRT that have a large primary tumor (T3-T4) and extensive lymph nodal involvement (N3-
disease). (35) 
This study showed that the 8th TNM edition was an independent statistically significant 
prognostic factor for SCLC patients after adjusting for clinical characteristics in the multi-
variate analysis. Given that most SCLC patients are diagnosed with locally advanced or 
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metastatic disease, the 8th TNM edition will not frequently alter the clinical management. 
Nevertheless, the 8th TNM edition should be incorporated into clinical research since more 
precise classification of subgroups could influence treatment approaches in the future. 
4.3 Treatment patterns and survival outcomes for SCLC patients – a Swedish single 
center cohort study (Paper III) 
Paper III was an RWD analysis of a large patient cohort (n=544) treated at Karolinska 
University Hospital and diagnosed between 2008-2016. The aim was to evaluate the 
treatment patterns and survival outcomes from Karolinska University Hospital compared to 
other studies. 
The survival outcomes of patients with ED in paper III were similar to previous studies. (35, 
117) However, the survival of patients with locally advanced disease was shorter compared to 
a large RCT. (174) One explanation for the discrepancy may be that monitoring of patients in 
a RCT is more intense, with more frequent follow-up visits and radiological scans, which 
subsequently leads to longer survival. (144) The number of patients that did not show signs of 
relapse was similar with historical data. (175)  
The survival outcomes for 2nd and 3rd line therapies, regardless of initial stage of disease, 
were very poor, illustrating the difficulty in treating patients after relapse occurs. (115) The 
main reasons for these results are that resistance mechanisms occurs rapidly in the course of 
the disease, together with a deteriorating PS. This can also in part explain the failure of 
molecular targeted agents and immunotherapies in the 2nd and 3rd line setting. (35, 115)  
The evidence of using re-challenge with PDCT is based on retrospective studies. (115, 119) 
In paper III, both LD and ED patients with Sensitive relapse (Sr) after PDCT had a longer 
median OS compared to the Resistant relapse (Rr) subgroup. Therefore, the length of PFS 
after 1st line PDCT can be a predictor for prognosis for 2nd line CT in both LD and ED 
patients. Patients without treatment for a longer time period may have a better PS when 
relapses occur compared to those with a shorter relapse-free interval. This enables the patient 
to better tolerate the next line of CT which may result in a longer survival. Another reason 
could be that the tumor has not developed platinum-resistance yet. (119) 
There were no significant differences in survival outcomes between CT regimens used in the 
monotherapy setting.   
Paper III had several limitations, including that data on tumor responses was not collected. 
Different radiological modalities were used and strict criteria to evaluate the treatment were 
therefore not feasible to carry out. Furthermore, there was an inconsistency between patients 
with regards to the timing of assessing the treatment response, with radiological scans 
performed after two up to five cycles of CT.  
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4.4 The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression 
in SCLC patients receiving platinum-based chemotherapy (Paper IV) 
In Paper IV the protein expression of Notch1, Hes1, Ascl1, and DLL3 were analyzed in 
biopsies of SCLC patients and their correlation to PDCT sensitivity as well as prognosis was 
investigated. These four biomarkers have not, to the best of our knowledge, been studied in 
the same cohort previously. (158, 176, 177)  
The results showed that Hes1, Ascl1, and DLL3 expression was found in most cases, while 
Notch1 expression was absent in the majority of samples. Both findings were in accordance 
to previous studies. (71, 154, 158, 177) A positive staining in the nucleus or cytoplasm was 
observed for Notch1, Hes1 and Ascl1, while DLL3 staining was confined to the plasma 
membrane. These staining patterns were in accordance with previous reports. (158, 176, 177)  
We found that Notch1 expression was an independent prognostic factors in the multi-variate 
analysis and that patients with Notch1-low tumor expression had a favorable prognosis. 
Notch1 expression has previously been linked to chemotherapy refractoriness consistent with 
a potential pro-tumorigenic role, which is in accordance with our results. (77) However, in 
another study on surgically resected SCLC samples (n=125), low Notch1 expression was an 
unfavorable prognostic factor. (177) These conflicting results highlights the need to future 
investigate the role of Notch1 with respect to PDCT sensitivity and prognosis in SCLC 
patients. Furthermore, a negative association between Notch1 and Ascl1 expression was 
found. This finding is supported by an earlier study which mechanistically reported that 
Ascl1 has the ability to reduce Notch1 at both transcription and post-translational level, the 
latter by protein degradation. (67)  
Hes1 expression was positive for most cases in paper IV, which substantiate in vitro results 
from a SCLC cell line where Hes1 expression was found in cell lines with neuroendocrine 
features. (178) Furthermore, there was no significant association between Hes1 and Notch1 
expression, which indicates that Hes1 expression is not solely regulated by Notch1. (76) 
A predictive or prognostic role of Ascl1 or DLL3 with regards to PDCT and OS was not 
observed in this study, in accordance with earlier reports. (154, 176) 
The results in paper IV are difficult to compare to previous studies, since this study mainly 
included stage IV patients while previous reports have investigated patients with surgically 
resected primary tumors. (35, 154, 176) 
In paper IV, a single diagnostic technique (IHC) was performed, which has been the most 
important diagnostic technique for SCLC diagnosis for decades. (151) However, the rapid 
development of more extensive testing is ongoing, including whole genome sequencing 
techniques which is illustrated by the human protein atlas and the proposed human tumor 
atlas. (179, 180) These growing databases will hopefully result in identifying new signaling 
pathways that can be targeted with small molecules that have improved efficacy and better 
toxicity profile compared to today’s standard of care. The highly complex biology behind 
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SCLC is yet to be fully understood, but it is clear that the Notch signaling pathway has an 
important role in both the development and resistance mechanisms in SCLC. (67, 72) Future 
studies on ADCs targeting the DLL3 expression are ongoing, which will hopefully generate 
more effective drugs for SCLC patients. (86)  
 24 
5 Conclusions 
Paper I showed that a lower level of education in men and LD SCLC patients was associated 
with a poorer prognosis compared to individuals with a high level of education. Future 
studies need to address these findings in order to minimize the discrepancies in survival 
outcomes between educational groups in SCLC.  
Paper II reiterated that the stage of SCLC is the most important prognostic factor for the 
disease. The 8th TNM edition provided an improvement in the nomenclature to describe 
characteristics of the tumor size and metastatic patterns as well as distinguish subgroups in 
SCLC. Further prospective studies are required to confirm the results of paper II. 
Understanding the outcomes and management for 1st, 2nd, and 3rd line CT and RT in paper 
III both informs and reflects clinical practice. The results emphasize the need for improving 
treatment options in SCLC, in all lines of therapy but especially for the majority of patients 
who eventually relapses after 1st line therapy.   
Paper IV focused on expression analysis of multiple proteins involved in the Notch signaling 
pathway. Notch1 was found to be a significant prognostic biomarker, which needs to be 
further validated on larger cohorts. DLL3 expression was positively stained in a majority of 
cases and this supports the notion that DLL3 continues to be a promising target.  
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6 Future Perspectives 
Despite advancements in understanding basic and clinical research regarding SCLC during 
the past decade, several questions remain to be answered in order to improve treatment 
options for this deadly disease.  
Strategies to achieve equal management for SCLC patients with different educational levels 
include more attention from healthcare professionals and a standardized program, which 
monitors compliance to treatment and offers social support. In order to improve the survival 
outcomes of SCLC patients, there is also a need to further understand the patterns of smoking 
cessation after SCLC diagnosis.   
The lack of new drugs for SCLC has been unsatisfactory during the past decades. (36) 
However, a new wave of enthusiasm has emerged in the field. The knowledge regarding 
survival outcomes and treatment patterns are important when designing clinical trials with the 
aim of improving the prognosis for SCLC patients.  
Enrolling a higher proportion of SCLC patients into clinical trials with obligatory biomarker 
analysis will be crucial to achieving better survival outcomes. This will require an active role 
of physicians treating SCLC patients as well as easing of eligibility requirements for clinical 
trials. SCLC is a very challenging disease to treat; however, my opinion is that the future for 
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